Introduction {#Sec1}
============

SARS-CoV-2 is an enveloped single positive stranded RNA virus responsible for the current pandemic of severe respiratory infections worldwide termed COVID-19 \[[@CR1]\]. SARS-CoV-2 infects tissues via its receptor, ACE2, and entry into cells requires spike protein cleavage by the serine protease TMPRSS2 \[[@CR2]\]. Although many reports of COVID-19 in pregnancy describe complications, such as preterm birth \[[@CR3]\], vertical transmission is apparently extremely rare \[[@CR4]--[@CR10]\]. Few reports of pregnancy and COVID-19 address placental infection rigorously and, to date, only two reports have demonstrated direct viral infection of the placenta \[[@CR9], [@CR10]\].

Although the villous syncytiotrophoblast (ST), which lines the surface of the placenta, provides a good barrier to placental infection, viral infections of the placenta do occur, and vertical transmission to the fetus has been demonstrated by many viruses most common are DNA viruses including CMV and HSV \[[@CR11]\]. These placental viral infections typically show a histological footprint of chronic inflammation in/of the villi (chronic villitis) or the intervillous space (intervillositis), or both \[[@CR11]\]. Infection occurs via either receptors on the villous ST or breaks in the villous trophoblast covering of the villous stroma allowing for infection of stromal cells particularly resident macrophages called Hofbauer cells \[[@CR12]\]. Infection of extravillous trophoblast (EVT) has also been demonstrated \[[@CR13]\]. Vertical transmission occurs when the virus gains access to fetal blood by direct placental infection or by fetal swallowing or aspiration of infected amniotic fluid.

RNA viruses can also infect the placenta often without causing characteristic histopathology. Exceptions include Hofbauer cell hyperplasia, chronic histiocytic intervillositis, and massive perivillous fibrin deposition (Supplementary Materials, Table [1](#MOESM1){ref-type="media"}). To date, a characteristic placental pathology has not been clearly demonstrated in placentas exposed to SARS-CoV-2. Three series that describe the placental pathology of placentas from COVID-19 patients show disparate results but suggest that coagulopathic findings might be common \[[@CR14]--[@CR16]\]. Another three cases have been described in which chronic histiocytic intervillositis was associated with placental infection and apparent vertical transmission \[[@CR9], [@CR10]\].

The question of whether SARS-CoV-2 infects the placenta is best answered by identifying cases with cellular evidence of viral infection. PCR detection of virus in placental homogenates or swabs is not definitive demonstration of placental infection as they may be contaminated by maternal cells. In addition, demonstration of tissue expression of ACE2 and TMPRSS2 would suggest the capability of the virus to infect the placenta and then possibly the fetus. Herein, we describe 19 placentas from mothers with COVID-19 studied for gross and histopathologic findings, viral expression by in situ hybridization (ISH) and immunohistochemistry (IHC), and ACE2 and TMPRSS2 expression by IHC. We find no specific gross or histopathologic findings in this cohort of COVID-19 exposed placentas. We found two cases of viral infection in the villous trophoblast. We demonstrate that ACE2 is expressed in a membranous pattern in the ST of the chorionic villi. We found that this expression pattern is biased toward the stromal side of the ST, away from the maternal lakes of the placenta. There is also membranous ACE2 expression in the cytotrophoblast (CT) and the EVT. No villous stromal cells, including Hofbauer cells, express ACE2. We demonstrate TMPRSS2 expression is weak and present in the villous endothelium and only rarely in the ST. We propose that these findings explain the limited placental and congenital infection by SARS-CoV-2.

Methods {#Sec2}
=======

Case acquisition {#Sec3}
----------------

With institutional review board approval (IRB2020P001116 and IRB2020P001001) and research support agreement (RSA2020A005296), the pathology department databases at the Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH), and The Beth Israel Deaconess Medical Center (BIDMC), in Boston, were searched for placentas with the clinical history of "COVID-19-positive" or "coronavirus-positive" from March 1, 2020 to May 15, 2020. Positive cases were then verified by reviewing the clinical history for laboratory values through healthcare records (EHR) at each institution. In total 19 maternal test positives were identified and were included in the study. One negative test was retained as a negative control (MGH3). RNA testing for SARS-CoV-2 was performed on nasopharyngeal swabs using FDA-cleared commercial assays performed according to the manufacturers' instructions.

We used three sets of controls for this study (Table [1](#Tab1){ref-type="table"}). First, although the specificity of our probe for the ISH has been demonstrated in pulmonary tissues \[[@CR17]\], we sought to control for its specificity in the placenta. Ten placentas of COVID-19 negative mothers (delivered either before the pandemic or with negative tests) with clinical histories focusing on infections by an RNA virus (one case each of Zika exposure, HIV infection, and Hepatitis C infection), two cases of intrauterine fetal demise, and with histopathologies associated with congenital infections and coagulopathies (one case each of high stage and grade acute chorioamnionitis, high grade maternal vascular malperfusion (MVM), high grade fetal vascular malperfusion (FVM), high grade villitis of unknown etiology (VUE), chronic histiocytic intervillositis, and multiple intervillous thrombi) were identified from the pathology database using this diagnostic terminology and used as this set of controls. In addition, we used 122 historic "normal" controls from uncomplicated term deliveries (Table [1](#Tab1){ref-type="table"}) to determine the background prevalence of placental histopathologic findings in Boston. These controls were pulled from 2000 to 2004 and were examined for the sole indication of maternal group B streptococcal (GBS) positivity by clinical history. Finally, we included "pathologic" controls identified in a database of placentas from neonates with a clinical diagnosis of hypoxic ischemic encephalopathy (HIE). This HIE database includes 130 placentas examined over 2 decades and includes late preterm and well as term neonates (Table [1](#Tab1){ref-type="table"}). All control placentas were obtained from the MGH.Table 1Controls.Control categoryNumber of placentas examinedAverage maternal age in years (range)Average gestational age in weeks + days (range)Average placental weight percentile {\[[@CR32]\], \#136} (range)For ISH probe specificity1031 (24--38)37 + 5 (31 + 6--40)\~34th (\<10→90)"Normal" controls = only GBS+ as indication for placental examination12228 (16--40)39 + 6 (37--41 + 4)\~34th (\<10→90)"Abnormal" controls = placentas from neonates with clinical diagnosis of HIE13031 (16--44)39 + 4 (33 + 6--43)\~30th (\<10→90)*GBS* group B Streptococcus, *HIE* hypoxic ischemic encephalopathy, *ISH* in situ hybridization.

Pathologic evaluation {#Sec4}
---------------------

All placentas were examined for gross and histologic findings at their respective institutions following the Amsterdam Consensus Statement guidelines \[[@CR18]\]. Pathologic diagnoses were rendered by experienced perinatal pathologists (DJR, BQ, JLH, CS) following published criteria \[[@CR11]\] categorized as shown in Supplementary Materials, Table [2](#MOESM1){ref-type="media"}.

Immunohistochemistry and ISH {#Sec5}
----------------------------

Formalin fixed and paraffin embedded (FFPE) blocks from each case and the control were chosen to include membranes, umbilical cord, and full thickness parenchyma. Five-micron serial sections were taken and divided for immunohistochemical (IHC) or ISH studies.

Immunohistochemistry was performed using an automated stainer (Bond-III; Leica Microsystems Bannockburn, IL) with ACE2 Monoclonal Antibody (clone CL4035 \[1:15,000\], Thermo Fisher Scientific, Waltham, MA), TMPRSS2 antibody (Clone PA5-83286 \[1:1,000\] Thermo-Invitrogen, Carlsbad, CA), and SARS Nucleocapsid Protein Antibody (clone NB100-56576 \[1:300\], Novus Biologicals, Littleton, CO) in accordance with the manufacturer's recommendations.

SARS-CoV-2 RNA ISH was performed using RNAscope® 2.5 LS Probe-V-nCoV2019-S Cat No. 848568 and, RNAscope® 2.5 LS Reagent Kit-RED Cat No. 322150 Advanced Cell Diagnostic (ACD), on automated BondRx platform (Leica Biosystems). Five-micron thick sections of FFPE placental tissues were used including umbilical cord, membranes, and full thickness parenchyma. All the steps from baking for 1 h at 60 °C to counterstain with hematoxylin were done on BondRx machine. RNA unmarking is done using Bond Epitope Retrieval Solution 2 for 15 min at 95 °C followed by protease treatment for 15 min and probe hybridization for 2 h. Signal was amplified by series of signal amplification steps followed by color development in red using (Bond Polymer Refine Red Detection, Leica) in the forms of red dots. Specificity of the probe has been previously described \[[@CR17]\] but was reinforced with ten placentas from COVID-19 mothers as described above.

Outcomes {#Sec6}
--------

We describe the histopathology of placentas exposed to maternal COVID-19 infections and compare our findings with published prevalence's and the two sets of selected controls. Viral infection of the placenta is examined by RNA and protein expression. Viral receptor and cofactor expression by IHC are provided. Data presented include limited clinical variables.

Role of the funding sources {#Sec7}
---------------------------

The sponsors of this study played no role in study design, data collection, methods, data analysis, data interpretation, or manuscript preparation. The senior author had full access to all the study data and takes final responsibility for the decision for manuscript submission.

Results {#Sec8}
=======

Clinical findings {#Sec9}
-----------------

Clinical variables are presented in Table [2](#Tab2){ref-type="table"}. Maternal age at delivery averaged 31 years (range 22--42 years, median 32 years) and most were multigravidas (16/19, 84%). All births except two (MGH2 and MGH11) were singletons. The maternal COVID-19 test was performed peripartum on all cases within an average of 3 days before delivery (range 9 days ante partum--5 days post partum). The gestational age at delivery averaged 35 3/7 weeks (range 22--41 1/7 weeks, median 36 4/7 weeks). Indications for delivery included maternal (spontaneous labor (*n* = 4), respiratory compromise from COVID-19 (*n* = 6), and preeclampsia (*n* = 3)), and fetal (abruption (*n* = 2), and nonreassuring fetal testing (*n* = 4)). The cesarean delivery rate was 60% with most performed for fetal indications. Most neonates did well in the early perinatal period except for a few cases with complications of prematurity (*n* = 8 of 21). One infant had complications related to intrapartum compromise (MGH8).Table 2Cases clinical features.CaseMAGPGA at delivery (weeks + days)Days from COVID+ test to deliveryMaternal COVID-19 symptoms peripartumIndication for deliveryRoute of deliveryBirth outcomeNeonatal courseFetal/Infant COVID test resultsMGH22410303Intubated/VentilatedTwinsNRFHTMaternal respiratory statusCSLivebirth X2Both twins to NICU with complications of prematurityEach twinNegative X2MGH3251033 + 4PP day 5 negativeNo symptomsPPROMVDLivebirthBenignNegative X2MGH4333040 + 17Mild SOB, myalgiasDecreased fetal activityNRFHTCSLivebirthBenignNegative X1MGH8333237 + 40No symptomsAbruption, DIC required gravid HysterectomyCSLivebirthNICU for neonatal encephalopathyNegative X1MGH9322036PP day 1Anosmia, fever, chills, fatiguePlacental previa, vaginal bleeding, laborCSLivebirthBenignPositive at 24 and 48 h of lifeMGH103753227Fever, cough, head- acheIUFDVDStillbirthStillbirthNot performedMGH11292130 + 60 (H/O +test at 23 weeks GA then −test X2 but + on admission to LD)AnosmiaTwinsPPROM/PTLNRFHT1 twin breechCSLivebirth X2Both admitted to the NICU with respiratory complications related to prematurityEach twin Negative X2MGH12322138 + 53No symptomsTerm laborVDLivebirthBenignNegative X1MGH13254236 + 33SOB, fever, cough, pneumonia on CXRMaternal respiratory Status, NRFHTCSLivebirthBenignNegative X1MGH14221041 + 10No symptomsSpontaneous laborVDLivebirthBenignNegative X1BWH2252139 + 53No symptomsSpontaneous laborVDLivebirthBenignNegative X1BWH4262137 + 22Rhinorrhea, coughCholestasisVDLivebirthBenignNegative X1BWH5394337 + 10Fever, low oxygen saturation in laborT2DMCSLivebirthMacrosomiaBenignNegative X1BWH6331038 + 30No symptomsPIH, FGRVDLivebirthBenignNegative X1BWH9354038 + 33No symptomsPETCSLivebirthBenignNegative X1BIDMC1363037.28DOE, coughcHTN, GDMCSLivebirthBenignNot performedBIDMC2343135.37Respiratory distress on 4 L O2 then intubated immediately PP, hypoxemia, coughMaternal respiratory status, breechCSLivebirthNICU for hypoglycemia and prematurityNegative X1BIDMC3282131.69Fever, "worsening respiratory symptoms" no supplemental O2, cough, malaise, myalgia, rashMaternal respiratory statusCSLivebirthNICU for respiratory distress, rash, and prematurityNegative X1BIDMC4422029.31Fever, no respiratory symptomsChronic abruptio, PPROM, decreased fetal activityVDLivebirthNICU for respiratory distress and prematurityNegative X1BIDMC5282135.55Respiratory difficulty on 2 L O2, cough, fever, hemoptysis, sore throat, myalgiaMaternal COVID symptoms, BreechCSLivebirthMild pulmonary immaturityNegative X1*cHTN* chronic hypertension, *CS* cesarean section, *CXR* chest X-ray, *DIC* disseminated intravascular coagulation, *DOE* dyspnea on exertion, *FGR* fetal growth restriction, *GDM* gestational diabetes mellitus, *H/O* history of, *HSV* herpes simplex virus, *IUFD* intrauterine fetal demise, *L* liter, *NRFHT* nonreassuring fetal heart testing, *PET* preeclampsia, *PIH* pregnancy induced hypertension, *PP* post partum, *PPROM* preterm premature rupture of membranes, *SOB* shortness of breath, *T2DM* type 2 diabetes mellitus, *VD* vaginal delivery.

The maternal COVID-19 respiratory status was mild except for in five women who had severe symptoms requiring supplemental oxygen, including one who was being mechanically ventilated at the time of delivery (MGH2) and one immediately after delivery (BIDMC2). Only one neonate who was tested, tested positive for SARS-CoV-2 24 h (MGH9) \[[@CR19]\]. There were no maternal or neonatal deaths in our series, but one (MGH10) was from a 22 weeks gestation intrauterine fetal demise.

Placental gross and histopathology {#Sec10}
----------------------------------

Placental pathologic, immunohistochemical, and ISH findings are presented in Table [3](#Tab3){ref-type="table"}. Placental gross and histopathologic features compared with the two control groups are summarized in Supplementary Materials, Table [3](#MOESM1){ref-type="media"}. Overall we found no specific gross or histopathology in placentas associated with exposure to SARS-CoV-2 (Table [3](#Tab3){ref-type="table"}). Grossly there were frequent umbilical cord insertional anomalies (30%, above the background reported prevalence of from 0.1 to 15% \[[@CR20]\]). Looking at the histopathology by category (Supplementary Materials, Table [2](#MOESM1){ref-type="media"}), we found any MVM at 25% (5 of 19 cases), which was similar that present in the "normal" controls (25% prevalence) and the "abnormal" controls (15% prevalence) or a reported background prevalence of 33% \[[@CR21]\]. Three of our MVM cases were low grade and two were high grade (MGH8 and MGH14) neither of which were associated with hypertensive disorders. These two cases had decidual arteriopathy (Fig. [1](#Fig1){ref-type="fig"}). Although there were no cases of massive perivillous fibrin deposition, one case had multifocal increased perivillous fibrin but not to the diagnostic criteria of MPFD (MGH14, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR22]\]. FVM was present in four cases (20%) but one was associated with an intrauterine fetal demise (MGH10) and, on review, was considered a postmortem pathology. Excluding this case, the 15% prevalence of any FVM in our COVID-19 associated placentas is within the published prevalence of FVM at from 7 to 20% \[[@CR23]\]. The case prevalence is higher than the prevalence present in our "normal" controls (5%), but similar to that present in our "abnormal" controls (17%). Thirty percent of cases were classified in the Infe COVID category but only one case was high grade (BWH5, Fig. [1](#Fig1){ref-type="fig"}). This prevalence is higher than that seen in our "normal" controls but less than in the "abnormal" controls. All the Infe COVID-19 associated cases were acute chorioamnionitis and four of the sixes cases had a fetal inflammatory response. Inflammatory pathologies were seen in 15% (3 of 19 cases) and all were either low grade or ungradeable. One case had focal Hofbauer cell hyperplasia (MGH9) and one case had histiocytic intervillositis (MGH12, Fig. [1](#Fig1){ref-type="fig"}), but not of a degree for a diagnosis of chronic histiocytic intervillositis \[[@CR24]\]. There was one case of VUE (5%), within the published prevalence of 5--15% \[[@CR25]\]. Our 15% prevalence of any inflammatory pathology compares with any inflammatory pathology in the "normal" controls (25/122, 20%) or the "abnormal" controls (15/130, 12%). If only scoring the Infl-HG placentas, we found 2 in 122 "normal" controls (1.6%) and 4 in 130 "abnormal" controls (3%), both above our cases at 0%.Table 3Pathologic features.CaseGAPlacental weight (g)Weight percentile \[[@CR32]\]Gross pathologyH&E microscopic pathologyH&E microscopic category/grade (see Table [2](#Tab2){ref-type="table"})ACE2 IHCTMPRSS2 IHCnCapsid IHCSARS-CoV-2 RNA ISHMGH230473 combined\~25thDDTP, circumvallation both twinsBoth twins with acute chorioamnionitis (maternal stage 1, grade 1)Twin B with focal AVV (FVM, LG)FVM/LGInfe/LGGrossST---circumferentialEVTCTScattered decidua parietalis cellsNegativeNegativeNegativeMGH333 + 4336\~10thMarginal insertion of the umbilical cordSubchorionic thrombusOther/LGGrossST---primarily biasedCTEVTScattered decidua parietalis cellsNegativeNegativeNegativeMGH440 + 1403\<10thNoneMeconium pigmentAcute chorioamnionitis(maternal stage 2, grade 1) with fetal inflammatory response (fetal stage 1, grade 1)Membrane myometrial fibersInfe/LGHypo/LGOther/LGST---biasedCTEVTScattered decidual parietalis cellsFocal in muscularized stem villous vessels wallsNegativeRare ST and CTMGH837 + 4428\~25thGreen discolored, 1 cm central firm parenchymal massMeconium pigmentDecidual arteriopathy with acute atherosisSingle small central placental infarct, usual typePatchy increased perivillous fibrinMVM/HGHypo/LGST---primarily biased, some circumferentialCTEVTScattered decidua parietalis cellsWeak in villous endotheliumNegativeNegativeMGH936469\~45thHypercoiled umbilical cord, central parenchymal mass not measuredSingle central placental infarct, usual type with peripheral increased perivillous fibrin,Hofbauer cell hyperplasia, focalMVM/LGInfl/LGGrossST---circumferentialCTEVTMaternal endotheliumScattered decidua parietalis cellsSpotty weak villous endotheliumMultiple foci of strong staining in STMultiple foci of strong staining in STMGH102254\<10thNonePostmortem AVV, VSK, SVOChorangiomatosisNecrotizing acute chorionitisPlasma cell deciduitisFVM/HG- postmortemInfe/LGInfl/LG Other/HGST---stromal biasedCTEVTNegativeNegativeNegativeMGH1130 + 6524\~30thFused DDTP, velamentous cord insertion twin APatchy chorangiosisHypo/LGGrossST---stromal biasedEVTDecidual parietalis stromal cells and maternal endotheliumNegativeMGH1238 + 5522\~60thGreen discolored membranes, Rightward coiled umbilical cordIMFDMeconium pigmentVUE, ungradeableIntervillositisFVM/LGInfl/LGHypo/LGGrossST---stromal biasedCTEVTNegativeMGH1336487\~65thNoneMeconium pigmentIMFDSubchorionic thrombusDecidual arteriopathy, hypertrophic typeAdherent basal plate myometrial fibersFVM/LGMVM/LGOther/HGST---stromal biasedEVTDecidual parietalis stromal cells and maternal endotheliumNegativeMGH1441 + 1353\<10th5 firm parenchymal regions up to 1.6 cm in sizeMultifocal regions of increased perivillous fibrinMVM/HGST---stromal biasedCTEVTNegativeBWH239 + 5518\~50thMarginal insertion of the umbilical cordAcute chorioamnionitis with fetal (maternal stage 1, grade 1) with fetal inflammatory response (fetal stage 1, grade 1)Infe/LGGrossST---circumferential with some stromal biasedCTEVTMaternal endotheliumDeciduaScattered decidua parietalis cellsNegativeNegativeNegativeBWH437595\>90thMarginal insertion of the umbilical cordAcute chorioamnionitis (maternal stage 1, grade 1)Meconium pigmentFetal normoblastemiaAdherent myometrial fibersInfe/LGHypo/HGOther/LGGrossST---stromal biasedCTEVTMaternal endotheliumDeciduaNegativeNegativeFocal positive maternal endothelial cells in decidua parietalisPlacenta-negativeBWH537 + 1797\>90thTrue knot of the umbilical cordAcute chorioamnionitis (maternal stage 1, grade 2) with fetal inflammatory response (fetal stage 2--3, grade 2)Intervillous thrombus with associated placental infarctInfe/HGOther/LGGrossST---stromal biasedCTEVTMaternal endotheliumRare umbilical artery endothelial cellsDeciduaWeak focal villous endothelial cells and stem vessel smooth muscleNegativeNegativeBWH638 + 3477\~45thRightward coiled umbilical cordDecidual arteriopathyMVM/LGGrossST---mix of circumferential and stromal biasedCTEVTScattered decidua parietalis cellsNegativeNegativeNegativeBWH938 + 3330\<10thVelamentous insertion of the umbilical cordNoneGrossST---circumferentialCTEVTDeciduaWeak in villous endotheliumNegativeNegativeBIDMC137 + 2526\~75NoneNoneNoneST---stromal biasedEVTDeciduaWeak in villous endothelium, negative in membranes and umbilical cordNegativeNegative in placental tissuesBIDMC235 + 3454\~60NoneNoneNoneST---stromal biasedEVTDeciduaWeak in villous endothelium, Umbilical cord endothelium and very weak and patchy in the STNegativeNegative in placental tissuesBIDMC331 + 6290\~10thNoneVillous edemaSubchorionic thrombusHypo/LGOther/LGST---stromal biasedEVTDeciduaVery weak in villous endothelium, negative in membranes and umbilical cordNegativeNegative in placental tissuesBIDMC429 + 3363\>90thNoneAcute chorioamnionitis (maternal stage 1, grade 1) with fetal inflammatory response (fetal stage 1, grade 1)Villous edemaInfe/LGHypo/LGST---stromal biased, rare circumferentialEVTSquamous metaplasia of amnion on umbilical cordWeak in villous endothelium, negative in membranes and umbilical cordNegativeNegativeBIDMC535 + 5518\~80thMarginal insertion of the umbilical cordNoneGrossST---stromal biasedEVTDeciduaWeak in villous endothelium, negative in membranes and umbilical cordWeak and focal in STNegative in placental tissues*AVV* avascular villi, *CT* cytotrophoblast, *DDTP* diamniotic dichorionic twin placenta, *EVT* extravillous trophoblast, *HG* high grade, *IHC* immunohistochemistry, *ISH* in situ hybridization, *LG* low grade, *ST* syncytiotrophoblast, *SVO* stem vessel obliteration, *VSK* villous stromal-vascular karyorrhexis, *VUE* villitis of unknown etiology.Fig. 1H&E Histopathology of COVID-19 exposed placentas.**a** Decidual arteriopathy with acute atherosis (MGH8), 10X. **b** Histiocytic intervillositis (MGH12), 40X. **c** Fetal inflammatory response in the umbilical vein extending into Wharton's jelly (BWH5), 10X. **d** Increased perivillous fibrin (MGH14), 10X.

ACE2 expression {#Sec11}
---------------

ACE2 was expressed in the ST in a membranous pattern with a polarity such that expression was strongest at the membrane adjacent to the CT and villous stroma (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). In many cases, the expression was restricted to the stromal side membrane (in 14 of the 20 cases total). ACE2 was also strongly expressed in the villous CT usually in a circumferential membranous pattern and present in a membranous, and occasionally in a cytoplasmic pattern, in scattered EVT in the decidua basalis and chorion laeve (Fig. [2](#Fig2){ref-type="fig"}). Maternal vessels showed strong staining present in endothelial cells and pericytes in the decidua parietalis (when present, Fig. [2](#Fig2){ref-type="fig"}). No ACE2 staining was present in villous stroma, Hofbauer cells, amniotic epithelium, or fetal endothelium.Fig. 2ACE2 and TMPRSS2 expression.Immunohistochemical stains for ACE2 at 60X showing case MGH3 (**a**, negative control) and case MGH9 (**b**) show membranous expression of ACE2 in syncytiotrophoblast and cytotrophoblast. Note the polarity of staining in **a** such that the strongest staining is on the villous stromal side of the syncytiotrophoblast (arrow) compared to the maternal lake side (arrowhead). This polarity is not present in case MGH9 as stain is present on the maternal lake side (arrowhead) and villous stromal side (arrow) in **b**. A syncytiotrophoblastic knot shows cytoplasmic staining in case MGH9 (arrow in **b**). This finding was focally present in all cases. Immunohistochemical stains for TMPRSS2 at 20X (case MGH3, **c**) and 40X (case BIDMC2, **d**). No stain is present in case MGH3 (**c**, negative control) but weak cytoplasmic staining is preset in the villous endothelium (arrow) and weak membranous staining in the ST (arrowhead) in case BIDMC2 (**d**). **e** ACE2 expression in the decidual parietalis maternal endoderm/pericytes (BWH4), 20X. **f** ACE2 expression in the EVT in the decidua basalis (BIDMC3), 20X.

TMPRSS2 expression {#Sec12}
------------------

In rare cases, TMPRSS2 expression was weakly positive in a cytoplasmic pattern in the villous endothelium (Fig. [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Only one case had TMPRSS2 staining in a membranous pattern very weakly and in a patchy distribution in the ST (BIDMC2, Fig. [2](#Fig2){ref-type="fig"}). Most cases were negative for any detectable expression of TMPRSS2.

Viral expression via IHC or ISH {#Sec13}
-------------------------------

Most cases were negative for any viral protein (18 of 19 by IHC) or RNA (17 of 19 by ISH) (Table [3](#Tab3){ref-type="table"}) in the placenta. ISH probe controls were all negative. Rare weak expression was detected by ISH in the maternal endothelium in the decidua parietalis in few cases. One case (MGH9) showed robust expression by both techniques in a patchy distribution in the ST (Fig. [3](#Fig3){ref-type="fig"}). One other case (MGH4) had very focal ST and CT expression only by ISH (Fig. [4](#Fig4){ref-type="fig"}). Neither showed FVM. MGH9 did show low grade MVM and Infl pathology (Table [3](#Tab3){ref-type="table"}).Fig. 3Viral expression via IHC and ISH.Left column of images from MGH3 (negative control). Right column of images from MGH9. H&E (**a**, **b**), immunohistochemical stains for nCapsid (**c**, **d**), and in situ hybridization for viral RNA (**e**, **f**), 20X.Fig. 4Viral expression via ISH in MGH4.Focal expression in the syncytiotrophoblast and cytotrophoblast at 40X (left panel) and 60X (right panel).

Discussion {#Sec14}
==========

Although there have been many reports of infants born to mothers tested to be SARS-CoV-2 positive \[[@CR3], [@CR7], [@CR26]--[@CR29]\], there are only rare case reports of probable vertical transmission \[[@CR4], [@CR5], [@CR9], [@CR10], [@CR30], [@CR31]\]. This suggests that SARS-CoV-2 either rarely infects the placenta or is prevented from transmission despite placental infection. We show that SARS-CoV-2 can infect the placental ST and CT (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). In addition, we show that ACE2, the receptor for SARS-CoV-2, is expressed in a membranous pattern in the ST and CT of the villi, and in both a membranous and cytoplasmic pattern in the EVT in the chorion laeve and decidua basalis (Fig. [2](#Fig2){ref-type="fig"}). We also report a unique polarized expression of ACE2 such that in most cases ST expression is strongest, and sometimes only, present in the cell membrane internal, or stromal, side of the trophoblast (Fig. [2](#Fig2){ref-type="fig"}). In addition, we find that TMPRSS2 is rarely expressed in the trophoblast and is expressed only weakly in the villous endothelium (Fig. [2](#Fig2){ref-type="fig"}).

Although we had no characteristic placental pathology in our cases from COVID-19 exposed placentas, we did see a spectrum of pathologies (Table [3](#Tab3){ref-type="table"}). Interestingly we saw only one case each of chronic villitis, intervillositis, and increased perivillous fibrin. Except for an increase in gross pathologies, the prevalence of the other categories was within our control groups and published series. The gross pathology findings are difficult to explain but are unlikely to be related to SARS-CoV-2 exposure.

To the authors knowledge, there are seven reports of placental findings related to SARS-CoV-2 exposure (Supplementary Materials, Table [1](#MOESM1){ref-type="media"}). In Baergen and Heller's report \[[@CR14]\], they that found 10 of 20 exposed placentas had FVM. Although not graded in their report, by description it is likely that four were high grade. Our prevalence of 15% of FVM (all low grade) is higher than our "normal" controls and this may be a real increase, similar to prevalence in our "abnormal" controls. The manuscript by Shanes et al. \[[@CR16]\] describes an increased prevalence of MVM in their series of 16 placentas delivered to women with COVID-19. Although there were only two cases with MVM in their series of 16, which was significantly above their robust controls. There is one manuscript \[[@CR15]\] that describes the placentas from three COVID-19 infected mothers in China. All three placentas were described as having increased perivillous fibrin. Baud et al. \[[@CR4]\] published a case of apparent placenta infection in a 19 weeks intrauterine fetal demise. The infection was detected by placental homogenate and swab PCR (which we believe may be contaminated by maternal tissue). Fetal tissues were negative for SARS-CoV-2. The figures demonstrate mild acute chorioamnionitis with a fetal inflammatory response. Although the authors conclude that there was increased perivillous fibrin and syncytial knots (both features of MVM), the image is not convincing. In our opinion, the findings are more consistent with the effects of retention of an intrauterine fetal demise. Our series found MVM in 25% of cases but that was within our control prevalence. Kirtsman et al. \[[@CR5]\] described CHI in a placenta from a case of potential vertical transmission. Three of these seven reports found features that suggest a coagulopathic process. Although we did see MVM and FVM in our series, we did not see them increased over published prevalence's or our two sets of controls. Two recent case reports describe placental infection by ISH in three cases \[[@CR10]\] and in one case \[[@CR9]\]. Both of these reports found infection in the ST as did we. Hosier et al. \[[@CR9]\] also demonstrated virus in the ST by electron microscopy. Three of these four cases demonstrated histiocytic intervillositis, as we saw in one of our cases, but not in either of our two cases with infection. We believe that our data and the published literature has not definitively identified a histopathologic footprint of SARS-CoV-2 infection of the placenta or features characteristic of exposure without infection.

We expected an increase in chronic inflammatory pathologies, particularly chronic villitis or chronic intervillositis, in these exposed placentas given what has been reported in other RNA viral infections (Supplementary Materials, Table [1](#MOESM1){ref-type="media"}). We did not see this in our cases. In our series, there are three cases with a chronic placental inflammatory process, but none are high grade. Although this represents a prevalence of 15% overall, there was only one case of chronic villitis (VUE, ungradeable) at 5%, within the accepted background prevalence published at from 5 to 15% \[[@CR25]\]. In the published literature, there are only case reports identifying a chronic inflammatory process, three identifying intervillositis \[[@CR5], [@CR9], [@CR10]\]. Intervillositis was seen in one of our cases (and was not one of the two cases with demonstrable placental infection) but has not been described in other series \[[@CR14], [@CR16]\]. Whether it is a true marker for SAR-CoV-2 placental infection needs more study.

Our morphologic study is limited in that we did not use optimal controls. We believe that the best controls would have been placentas delivered to women with COVID-19 symptoms (e.g., hypoxia) but SARS-Cov-2 test negative. This should be done to definitively identify if coagulopathic or inflammatory pathologies are increased in this population. In our one placenta from a symptomatic but COVID-19 test negative woman, the placenta showed a subchorionic thrombus (MGH3).

In summary, we show that ACE2 is expressed in the trophoblast of the placenta with a polarized membranous pattern in the ST. We also show that TMPRSS2 is expressed weakly mainly in the chorionic villous endothelium. We demonstrate SARS-CoV-2 virus infection of the ST and CT. This is conclusive evidence of placental infection and therefore confirms the possibility of vertical transmission. As we have no definitive cases of congenital infection, these data suggest that placental infection may not always equate with vertical transmission.
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